CXL: Industrial Decarbonisation Pioneer - Licensing Dreams, Demonstration Realities

Calix Limited operates as a pre-commercial technology platform developing proprietary indirect heating solutions for industrial decarbonisation across cement, steel, lithium, and alumina sectors. The company transitions from low-margin water treatment products (86% current revenue) toward high-margin licensing royalties contingent on successful demonstration projects over 2026-2028.

• Market Position: Pre-commercial with validated pilot demonstrations (Leilac-1 operational since 2019, ZESTY 130+ ore tests); targeting 8-12% cement/lime market share and 5-8% green iron penetration by 2035 against competing technologies demonstrating in parallel.
• Financial Performance: Revenue $28.2m (FY25) growing 16% CAGR to $137m (FY35); EBITDA margin -88% improving to +15% breakeven (FY30), +54% (FY35); licensing inflection FY28-30 drives profitability with 90% gross margins offsetting current $28.7m annual cash burn.
• Valuation: Trading $0.55 versus fair value $0.68 (24% upside); 91.4% terminal value dependency reduces DCF weight to 36%, elevating asset-based valuation (64% weight) comprising net cash $23m, Magnesia business $20m, technology IP $35m, PLS JV equity $15m.
• Investment Assessment: Probability-weighted expected return 15% annually over three years against maximum 55% downside to liquidation value $0.22; suitable for patient capital tolerating 18-month cash runway, binary demonstration outcomes (60-80% success probability per application), and 5-7 year competitive advantage period before margin compression.

Key catalysts: Mid-Stream lithium commissioning December 2025, Leilac-2 construction commencement mid-2026, ZESTY financing closure FY26. Primary risks: demonstration failure (35-40% probability), policy reversal (25-30%), funding shortfall (30%), extreme terminal dependency creating ±$0.15-0.20/share sensitivity to margin/growth assumptions.

Calix Limited operates as a pre-commercial technology platform developing proprietary indirect heating solutions addressing industrial decarbonisation across cement/lime CO2 capture (Leilac), green iron/steel production (ZESTY), lithium processing (Mid-Stream), and alumina calcination (ZEAL). The business model transitions from low-margin water treatment products (Magnesia segment, 86% of FY25 revenue $24.3m) toward capital-light licensing royalties generating 90% gross margins once commercial demonstrations validate technology at scale over 2026-2028. Strategic partnerships with Heidelberg Materials (global cement major, 150 plants, exclusive Leilac licensing), Pilbara Minerals (45% JV Mid-Stream lithium demonstration), and Heirloom (DAC exclusive) provide industrial credibility and risk-sharing for $100-200m demonstration capital requirements.

Recent financial performance demonstrates operational progress despite pre-profit status: FY25 revenue $28.2m (+19% YoY) driven by Magnesia capacity expansion (Queensland facilities, Unitywater and Gold Coast contracts) and Leilac engineering services ($3.8m, pre-licensing studies). However, EBITDA margin -88% ($-23.8m loss) reflects deliberate R&D investment ($17.8m, 63% of revenue) funding demonstration projects ahead of licensing inflection. Operating cash flow -$28.7m and free cash flow -$38.9m (including $10.3m capex) create 18-month runway from net cash position $23.0m (FY25 exit), necessitating assumed $15m equity raise FY26 at $0.60/share (14% dilution). Management executed decisive cost discipline: 23% H2 reduction ($22.3m→$17.1m quarterly OpEx) via headcount restructuring (155→108 employees) preserving runway whilst maintaining demonstration timelines.

Current competitive position reflects early-stage validation: water treatment <1% global market share (niche municipal Magnesia), cement/lime 0% (pre-commercial Leilac), green iron 0% (pre-commercial ZESTY). Competitive moat 4.5/10 overall comprises technology IP (32 patent families expiring 2025-2035), operational data advantage (Leilac-1 operational since 2019 provides 5-year head start), and strategic partnerships, but CAP duration limited to 5-7 years before competitive compression from alternative technologies demonstrating in parallel. Balance sheet strength adequate: essentially debt-free ($0.1m vehicle financing only), current ratio 1.56x, but constrained by 18-month cash runway and binary demonstration outcomes (60-80% success probability per application per Stage 4 risk analysis). Recent strategic initiatives include ARENA grant $44.9m secured July 2025 (50% matched funding for ZESTY demonstration), Mid-Stream lithium commissioning targeted December 2025 (80% complete, restarted February 2025 after October 2024 pause during lithium price collapse), and Leilac-2 construction targeted mid-2026 (delayed 6 months by Heidelberg relocation decision Hanover→Ennigerloh Germany).

Value creation over the next 12-24 months hinges on successful demonstration project execution validating commercial scalability and triggering licensing revenue inflection FY28-30. Near-term catalysts include Mid-Stream lithium commissioning (December 2025 target, 80% complete) requiring >90% spodumene recovery rate to secure PLS commitment for commercial scale-up Phase 2; Leilac-2 construction commencement (mid-2026 target) dependent on permitting approval Q2 2025 and financing closure H2 2025 ($30-40m beyond grants); and ZESTY financing closure (FY26 target) securing $50m+ matching funds beyond ARENA $44.9m grant. Policy environment provides critical validation: EU ETS carbon price stability above €70/t (current level) supports Leilac business case (€30-50/t capture cost versus €60-80 amine alternative), whilst U.S. DOE policy clarity Q1-Q2 2025 determines Heirloom DAC project timeline and 45Q tax credit durability.

Growth trajectory follows three-phase evolution: Phase 1 (FY26-28) dominated by Magnesia capacity utilisation improvements (72%→82%) and Leilac engineering services ($4-6m annually, pre-licensing studies) whilst demonstrations progress; Phase 2 (FY28-30) licensing inflection as first royalties commence (Leilac-2 operational mid-2026→18-month ramp→FY28 commercial, Mid-Stream Dec-25→FY28 licensing, ZESTY 2028→FY30+ royalties) driving revenue acceleration from $44.5m (FY28) to $64.6m (FY30); Phase 3 (FY30-35) penetration gains via Heidelberg fleet deployment (targeting 30 Leilac plants by FY35 = 10-12% market share) and lithium/green iron licensing scale-up ($62.6m Sustainable Processing revenue FY35). Execution requirements include maintaining 70% grant success rate (versus 20-30% industry benchmark) for matched funding leverage, managing resource allocation across four applications with 108 employees post-restructuring, and securing subsidiary financing without excessive parent company dilution.

Competitive dynamics evolve as alternative technologies demonstrate in parallel: conventional H2-DRI announcements (HYBRIT Sweden operational 2026, ArcelorMittal projects) and amine capture demonstrations by incumbents (Amine, MHI) create winner-take-most dynamics 2025-2028. CAP duration 5-7 years (2026-2032) before competitive equilibrium drives margin compression from initial 60-70% EBITDA licensing advantage to 45% terminal as customer bargaining power increases and operational data advantage commoditises. Major uncertainties include demonstration failure risk (35-40% probability one major project fails to achieve >75% performance targets), policy reversal risk (25-30% probability EU ETS <€50/t or US 45Q repealed eliminates addressable markets), and funding shortfall risk (30% probability unable to secure matching funds forces strategic retreat to Magnesia-only business valued $0.35-0.42/share). Scenario outcomes range from Best Case $1.20/share (all demonstrations succeed ahead of schedule, carbon pricing €150/t by 2028, market share exceeds targets) to Severe Case $0.26/share (multiple demonstration failures plus policy reversal, company limited to Magnesia commodity business).

Calix's business model comprises two distinct components: legacy Magnesia water treatment products (86% FY25 revenue, 40% gross margins, commodity positioning) providing operational cash flow stability during commercialisation phase, and emerging licensing platform (14% FY25 revenue transitioning to 70-75% terminal) generating high-margin royalties ($3-15/tonne cement/lime, $5-10/tonne green iron, $120-150/tonne lithium) from proprietary indirect heating technology. The licensing model proves capital-efficient: demonstration projects externally funded via 50% government grants (ARENA, DOE, EU Innovation Fund) plus strategic partner contributions (Heidelberg JV, PLS 45% equity), minimising parent company capex whilst retaining IP ownership and royalty streams. Revenue transition follows staggered demonstration timeline: Mid-Stream lithium Dec-25 commissioning→FY28 licensing, Leilac-2 mid-2026 operational→FY28 royalties, ZESTY 2028 operational→FY30+ licensing, creating portfolio diversification across four industrial decarbonisation applications accessing $50bn+ addressable markets.

Competitive advantages derive from first-mover positioning and operational data accumulation: Leilac-1 operational since 2019 provides 5-year head start versus competing carbon capture technologies demonstrating 2026-2028, whilst ZESTY pilot 130+ ore tests (9 ore types including Australian hematite/goethite) demonstrate materials science depth and ore flexibility advantages. Technology IP comprises 32 patent families filed 2005-2015 (20-year protection expiring 2025-2035) covering indirect heating, CO2 capture, and metals processing applications. Strategic partnerships provide validation and market access: Heidelberg Materials exclusive licensing (150 plants globally across 5 continents), Heirloom DAC exclusive (direct air capture application), and PLS 45% JV (lithium processing demonstration with free-carried equity creating $15.1m non-cash gain FY25). However, moat strength 4.5/10 overall reflects narrow durability: current 3/10 pre-commercial (minimal advantages until validation), inflection 6-7/10 if demonstrations succeed (first-mover crystallises, switching costs activate as $30-100m retrofit capex creates lock-in), terminal 4-5/10 post-compression (patents expire, operational data commoditises, customer bargaining power increases).

Market dynamics bifurcate between policy-driven demand creation and competitive intensity: EU ETS phase-out 2026-2034 forces cement industry adoption (carbon price €70/t current, €150/t FY30 target creates economic forcing function), US 45Q $85/tonne CO2 tax credit supports business case, Australia FMIA $22.7B green metals package funds demonstrations. However, competing technologies race to commercial validation in parallel—conventional H2-DRI, amine capture, alternative licensing platforms—creating winner-take-most dynamics where 2-3 proven solutions capture majority of market by 2030-2032, compressing Calix's CAP duration to 5-7 years before competitive equilibrium. Management assessment 7.2/10 reflects sophisticated strategic thinking (platform approach across multiple sectors) and exceptional grant funding capability (70% success rate versus 20-30% industry = competitive advantage), offset by commercial execution gaps (FY24 milestone misses, timeline extensions requiring 25-30% haircut to guidance) and resource constraints (108 employees managing four applications simultaneously creates "spreading too thin" risk). Capital allocation discipline strong: zero M&A, zero dividends/buybacks appropriate for pre-profit stage, but equity raise timing (December 2024 $22.1m at $0.75/share, 9% below calculated fair value $0.68 after terminal dependency adjustments) suggests forced dilution under 18-month runway duress versus discretionary poor judgment.

FY25 results demonstrate operational progress within pre-commercial constraints: revenue $28.2m (+19% YoY) driven by Magnesia segment $24.3m (+16% YoY, capacity expansion Queensland facilities plus Unitywater and Gold Coast contract wins) and Leilac services $3.8m (+19% YoY, engineering studies for demonstration construction phase). Gross profit $10.1m declined -$1.2m YoY despite revenue growth as product mix shifted toward lower-margin equipment rentals versus direct sales (mix index 0.98 versus 1.00 prior year). EBITDA loss -$23.8m improved from -$26.9m FY24 (+11% reduction) reflecting H2 cost discipline: operating expenses declined 23% H2 versus H1 ($22.3m→$17.1m quarterly) via headcount restructuring 155→108 employees generating $6-8m annualised savings whilst maintaining demonstration timelines. Operating cash flow -$28.7m (versus -$20.6m FY24) and free cash flow -$38.9m (including $10.3m capex, down from $15.1m FY24) consumed runway, offset partially by December 2024 equity raise $22.1m at $0.75/share extending liquidity to 18 months.

Operational metrics reveal mixed execution: Magnesia utilisation 72% (FY25) improved from 68% (FY24) as Queensland expansion ramped, but below 82-85% steady-state target indicating further operational leverage potential. Days Sales Outstanding increased 52% to 35 days (FY25) from 23 days (FY24) signalling industrial customer payment term stretching and broader B2B liquidity tightening, whilst inventory days 8 (stable) reflect just-in-time Magnesia production model. R&D expenses $17.8m (63% of revenue) declined from $21.4m FY24 peak as Leilac-1 operational learnings transitioned to Leilac-2 engineering phase, but remain elevated funding ZESTY pilot completion (130+ ore tests) and Mid-Stream demonstration (80% complete by FY25 exit). Management commentary emphasised three priorities: (1) cost discipline achieved via restructuring preserving 18-month runway, (2) demonstration project progress on-track despite external delays (Leilac-2 relocation, Mid-Stream lithium pause/restart, U.S. DOE reviews), and (3) grant funding success continuing with ARENA $44.9m secured July 2025 demonstrating 70% success rate versus 20-30% industry benchmark. Balance sheet position adequate: current ratio 1.56x (down from 2.05x FY24), debt-to-equity 0.0x (essentially debt-free), but 18-month cash runway creates execution constraint requiring assumed FY26 equity raise $15m at $0.60/share (14% dilution) to extend liquidity through demonstration validation period 2026-2028.

Revenue projections follow three-phase trajectory: Phase 1 (FY26-28) Magnesia capacity expansion driving 20%→9% growth as Queensland facilities reach 82-85% utilisation plus Leilac engineering services $4-6m annually (pre-licensing studies); Phase 2 (FY28-30) licensing inflection as first royalties commence (Leilac $1.8m FY28→$7.5m FY30, lithium $3m FY28→$15.8m FY30) whilst services decline; Phase 3 (FY30-35) penetration gains via Heidelberg fleet deployment (30 Leilac plants by FY35 = $26.4m royalties) and Sustainable Processing scale-up ($62.6m FY35 comprising lithium $57.6m + green iron $3.0m + alumina $1.5m). Consolidated revenue CAGR 16% (FY26-35) reflects segment-specific multi-factor models: Magnesia capacity×utilisation×price (52kt→72kt capacity, 72%→85% utilisation, $620→$784/t pricing), Leilac plants×capacity×royalty (0→30 plants, 100-150kt CO2/yr, $5-15/t), lithium plants×spodumene×royalty (0→8 plants, 25-35kt capacity, $120-150/t).

Margin progression reflects business model transition from product-dominated (37% gross margin FY25, Magnesia 86% revenue mix) to licensing-dominated (79% gross margin Terminal, licensing 75% revenue mix at 90% gross margins). EBITDA margin inflection occurs FY28-30 as licensing revenue scales and fixed costs leverage: -88% (FY25)→-52% (FY26)→-22% (FY28)→+15% (FY30 breakeven)→+54% (FY35)→45% (Terminal competitive equilibrium). Terminal EBITDA margin 45% reflects Stage 6 competitive equilibrium correction from preliminary 63%, modelling 5-7 year CAP duration before margin compression as alternative technologies demonstrate, customer bargaining power increases, and operational data advantage commoditises post-2030. Operating leverage (DOL) averages 2.6x across forecast period: 1.0-1.5x near-term (FY26-27, pre-licensing, product business characteristics), 2.4x transition (FY28, licensing inflection), 6.6x inflection spike (FY30, EBITDA crosses breakeven creating mathematical anomaly), normalising 2.0-3.0x steady-state (FY31-35, licensing platform mature).

Key assumptions underpin projections: WACC 13.9% (Stage 6 Path A standard market-based, no premiums) reflects pre-commercial technology platform risk via elevated equity beta 1.8-2.0; terminal growth 3.0% aligns with GDP (mature licensing market growing with industrial production); tax rate 0% FY26-30 (loss-making, NOLs accumulated) transitioning to 30% FY31+ (Australian statutory, blended with U.S./EU licensing income). Capital intensity remains low: maintenance capex 2.1-2.4% revenue (Magnesia facilities + corporate), working capital improving from 18% sales (FY25, inventory and receivables for product business) to 6% terminal (licensing model minimal WC requirements). Profitability floors enforced: EBITDA ≥15% by Year 3+ (achieved FY30), EBIT ≥0% by Year 3+ (delayed to FY31 due to D&A burden, acceptable for technology platform where licensing revenues require 2-3 years post-commencement to scale above fixed OpEx). Sensitivity analysis reveals extreme terminal dependency: 91.4% of enterprise value derived from terminal assumptions (Stage 9) versus 60-75% industry norm, creating ±$0.15-0.20/share value swings from small changes in terminal margin (45%±5pp), growth (3.0%±0.5pp), or WACC (13.9%±50bps).

DCF & Relative Valuation

DCF Base Case generates $0.95/share fair value (pre-probability weighting) via 10-year explicit forecast (FY26-35) discounted at WACC 13.9%, terminal value calculated using hybrid method: 50% perpetuity growth (terminal FCF $56.4m / [13.9%-3.0%] = $517m) plus 50% EV/EBITDA multiple (terminal EBITDA $86.1m × 9.0x = $775m), yielding $646m terminal value. However, 91.4% terminal dependency (PV of terminal $175.7m / total EV $192.3m) triggers sigmoid DCF weight reduction from 50% traditional to 36% dynamic (multiplier 0.16 = 84% confidence haircut), mechanically reducing fair value contribution. Probability-weighting applies Stage 4 scenarios: Base 60% ($0.95), Bear 30% ($0.42, one major demo fails OR policy weakens 40%), Severe 10% ($0.26, multiple demos fail + policy reversal), yielding $0.71 probability-weighted DCF. Relative valuation unavailable: no comparable public peers for pre-commercial industrial decarbonisation technology platforms (Carbon Clean, Boston Metal private; ASX-listed industrials mature product companies not comparable).

Scenario Analysis

Scenario framework captures binary demonstration outcomes and policy dependency: Base Case (60% probability) assumes all priority demonstrations succeed on-time (Leilac-2 mid-2026, ZESTY 2028, Mid-Stream Dec-25), policy maintains (EU ETS €150/t, US 45Q stable, FMIA implemented), licensing revenues commence FY28-29, market share achieves 8-12% Leilac and 5-8% ZESTY by FY35, margins compress to 45% terminal competitive equilibrium by Year 10. Bear Case (30% probability) models one major demonstration failure (ZESTY uneconomic or Leilac-2 delayed 12+ months) OR policy weakens 40% (EU ETS €80/t), licensing revenue -50% versus Base, margin compression accelerates (40% EBITDA by Year 7), Magnesia insulated (100% of Base). Severe Case (10% probability) reflects multiple demonstration failures (Leilac-2 AND ZESTY) plus policy reversal (EU ETS <€50/t, US 45Q repealed), licensing revenue -80-90% versus Base, company limited to Magnesia cash generation (~$3m EBITDA = 10% of Base equity value). Probability-weighted expected value $0.64/share (versus current $0.55 = 16% upside) with 70% confidence interval $0.44-$0.92 (reliability score 53.6/100 = LOW confidence tier, ±35% bands appropriate).

Market Pricing Dynamics

Current price $0.55 versus fair value $0.68 represents 19% discount, but reverse DCF analysis reveals market pricing realistic commercialisation probability. Implied assumptions at $0.55: terminal ROIC ~10-11% (versus model 14%), revenue CAGR ~12-13% (versus model 16%), or terminal EBITDA margin ~38-40% (versus model 45%), collectively suggesting market assigns 40-50% probability to successful platform commercialisation versus 60% Base case weighting. This market skepticism appears rational given: (1) extreme terminal dependency 91.4% creates forecast risk where small assumption changes generate ±$0.15-0.20/share swings, (2) binary demonstration outcomes with 35-40% probability one major project fails, (3) 18-month cash runway requiring FY26 equity raise creating near-term dilution overhang, and (4) competing technologies demonstrating in parallel 2026-2028 eroding first-mover advantage if Calix experiences delays. December 2024 equity raise at $0.75/share (institutional participation) suggests sophisticated investors pricing 50-60% commercialisation success, aligning with fundamental analysis versus prior market enthusiasm (December 2023 highs $4.70 implied >80% success probability, subsequently corrected).

Behavioral and structural drivers sustaining the 19% discount include: (1) Cleantech valuation compression (sector-wide phenomenon, CTVC Index -40% 2023-24) driven by rising interest rates reducing NPV of long-dated cash flows and risk appetite collapse for pre-revenue platforms requiring patient capital; (2) Liquidity preference shift toward quality/profitability as late-cycle positioning favors defensive industrials over growth assets, evidenced by DSO increase 52% (35 days FY25 versus 23 days FY24) signaling industrial customer payment term stretching; (3) Anchoring bias to historical losses (EBITDA margin -88% FY25, cumulative losses -$69.7m FY23-25) preventing market from fully pricing licensing inflection FY28-30 despite operational validation (Leilac-1 since 2019, ZESTY 130+ tests, 70% grant success rate); (4) Small-cap illiquidity premium ($100m market cap post-Dec 24 raise) where ASX micro-cap technology platforms trade at structural discounts to intrinsic value absent institutional coverage or index inclusion. These forces prove durable near-term (12-18 months) but vulnerable to demonstration validation catalysts.

Convergence catalysts with probability estimates and timing: Primary catalyst (probability 65%, horizon 12-18 months) = successful demonstration trifecta (Mid-Stream >90% recovery Dec-25, Leilac-2 construction commencement mid-2026, ZESTY financing closure FY26) validates technology platform and triggers re-rating toward $0.80-0.95 range as binary risk resolves and licensing inflection becomes visible; Secondary catalyst (probability 50%, horizon 18-24 months) = policy acceleration (EU ETS carbon price >€100/t by 2026 versus €70 current, or US 45Q expansion) creates urgency for industrial retrofits and expands addressable markets, supporting premium valuation multiples for proven decarbonisation solutions; Tertiary catalyst (probability 40%, horizon 24-36 months) = strategic acquisition interest (Heidelberg Materials, cement major, or private equity) emerges post-demonstration validation, offering 2-3x current valuation ($1.40-2.10 range) for technology platform with proven commercial scalability. Early warning signals: Mid-Stream commissioning results (December 2025 quarter), Heidelberg Materials capex guidance (FY24 Results February-March 2025 indicating multi-year Leilac rollout commitment or delays), EU ETS carbon price trajectory (sustained >€85 bullish, <€60 bearish), and cleantech funding environment recovery (CTVC Index +20% from lows, IPO window reopening for pre-revenue platforms indicating risk appetite returning).

Technology commercialisation execution risk (35-40% probability, -$0.26/share Bear case impact) represents primary investment uncertainty: transitioning from pilots to commercial licensing across four sectors simultaneously strains resources (108 employees post-restructuring managing demonstrations plus Magnesia operations), with 30% probability of material delays (12+ months) requiring dilutive financing and 10% probability demonstration failure writing off $10-20m sunk R&D per application. Mitigation via portfolio approach diversifies binary outcomes—failure of one application (e.g., ZESTY 40% failure probability) doesn't eliminate licensing platform given cement/lime (60% equity value potential), lithium (10%), and alumina (terminal optionality) provide resilience, whilst Magnesia segment EBITDA +8-12% throughout forecast ($2-3m annually) demonstrates operational viability supporting consolidated losses during commercialisation phase.

Extreme terminal value dependency (91.4% of enterprise value, structural characteristic not probability-based risk) creates ±$0.15-0.20/share sensitivity to small assumption changes: terminal EBITDA margin 45%±5pp, terminal growth 3.0%±0.5pp, or WACC 13.9%±50bps each generate material value swings given limited near-term cash flow contribution (8.6% of EV from FY26-35 explicit period). This dependency reflects pre-commercial business model where licensing revenues 3-5 years out drive valuation versus current negative cash generation, analogous to biotech pre-FDA approval or SaaS pre-recurring revenue scale—mitigation requires scenario probability-weighting (Base 60%, Bear 30%, Severe 10%) capturing range of outcomes and asset-based valuation floor $0.65/share (64% weight) providing downside anchor independent of terminal assumptions.

Government policy dependency (25-30% probability reversal, -$0.20/share Severe case impact) stems from 50%+ reliance on grants (operational support, $60m+ secured at 70% success rate) and policy-driven demand (carbon pricing creates addressable markets—EU ETS, US 45Q, Australia FMIA). Evidence includes U.S. DOE review pausing projects FY25 and Trump administration policy uncertainty, whilst EU ETS carbon price €70/t (down from €84 peak) demonstrates volatility. Mitigation strategies include geographic diversification (three jurisdictions reduces single-policy dependency), portfolio approach (multiple applications across cement, steel, lithium, alumina), bipartisan US 45Q support (oil/gas state backing provides durability versus renewable subsidies), and EU ETS legislated through 2034 (phase-out timeline provides regulatory certainty). Funding shortfall risk (30% probability, -$0.20/share impact) arises from 18-month cash runway requiring precise execution: assumed FY26 parent company equity raise $15m at $0.60/share (14% dilution) extends runway to FY28, but subsidiary financing gaps persist (Leilac-2 requires $30-40m beyond grants, ZESTY $50m+ beyond ARENA $44.9m)—if project finance unavailable, forces strategic retreat to Magnesia-only business valued $0.35-0.42/share. Competitive displacement (30-35% probability, -$0.15/share impact) reflects CAP duration 5-7 years before margin compression as alternative technologies demonstrate (conventional H2-DRI, amine capture) and customer bargaining power increases, modeled via terminal EBITDA margin 45% (competitive equilibrium) versus initial 60-70% advantage—if CAP shorter than 5 years due to competitor breakthrough 2026-2028, terminal margin compresses to 35-40% creating additional -$0.15-0.20/share downside.